Biofrontera on SPi NewsFollow our SPi News RSS Feed for biofrontera

Featured biofrontera News

[12 Jun 2019] Biofrontera to Present at Two Upcoming Investor Conferences

[04 Jun 2019] Biofrontera nominates new candidate for the Supervisory Board

[29 May 2019] Biofrontera Reports First Quarter 2019 Financial Results

[29 Apr 2019] Biofrontera Reports Full Year 2018 Financial Results

[26 Apr 2019] Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019

[25 Mar 2019] Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA

[11 Feb 2019] Biofrontera implements new Falsified Medicines Directive

[08 Jan 2019] Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production

[26 Nov 2018] Biofrontera to Participate in Two Upcoming Investor Conferences

[16 Nov 2018] Biofrontera reports earnings results for the third quarter and first nine months of 2018

[24 Sep 2018] Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference

[19 Sep 2018] Biofrontera to present at the Baader Investment Conference

[12 Jun 2018] Biofrontera files lawsuit against W.K.T. Zours, Deutsche Balaton AG and further defendants

[30 May 2018] Biofrontera Reports First Quarter 2018 Financial Results

[30 Apr 2018] Biofrontera Reports Full Year 2017 Financial Results

[15 Mar 2018] Biofrontera AG Announces Partial Waiver of Lock-Up Agreement

[15 Apr 2016] Biofrontera AG: Biofrontera Reports Full Year 2015 Financial Results

[15 Apr 2016] Biofrontera AG: Biofrontera Reports Full Year 2015 Financial Results

[07 Apr 2016] Biofrontera AG: Notice of Annual Results 2016

[07 Apr 2016] Biofrontera AG: Notice of Annual Results 2016

[04 Apr 2016] Biofrontera Announces NDA Progress Update for BF-200 ALA

[04 Apr 2016] Biofrontera Announces NDA Progress Update for BF-200 ALA

[16 Feb 2016] Biofrontera AG: Biofrontera AG resolves on capital increase

[16 Feb 2016] Biofrontera AG: Biofrontera AG resolves on capital increase

[12 Sep 2015] Ad hoc: Biofrontera AG - FDA accepts filing of Ameluz® and BF-RhodoLED® application

[14 Aug 2015] Biofrontera progresses well in first half year 2015

[07 Aug 2015] Biofrontera AG: Notice of First Half Year Results 2015

[22 Jul 2015] Biofrontera appoints Christoph Dünwald as Chief Commercial Officer

[13 Jul 2015] Biofrontera submits New Drug Application for Ameluz® to FDA

[22 Jun 2015] Biofrontera completes final steps ahead of FDA New Drug Application in the USA

[29 May 2015] Biofrontera delivers excellent business development in Q1

[27 May 2015] Ad hoc: Biofrontera AG - 1,377,272 shares placed in capital increase

[22 May 2015] Biofrontera AG: Notice of First Quarter Results 2015

[23 Apr 2015] Ad hoc: Biofrontera AG resolves on capital increase

[20 Apr 2015] Biofrontera establishes subsidiary in the US

[17 Apr 2015] Biofrontera starts with robust growth into the new year

[10 Apr 2015] Biofrontera AG: Biofrontera significantly increases its turnover in Germany in 2014

[08 Apr 2015] Biofrontera stabilizes shareholder structure

[25 Mar 2015] Biofrontera starts Sales and Marketing of Ameluz® in Spain

[05 Dec 2014] Biofrontera launches new addition Belixos® Gel to its derma-cosmetic line

[26 Nov 2014] Further progress in international approval processes of Biofrontera's Ameluz®

[13 Nov 2014] Biofrontera publishes report on the third quarter of 2014

[07 Nov 2014] Ad hoc: Biofrontera to take over the sales and marketing of Ameluz® in Spain from Allergan

[03 Sep 2014] Ad hoc: Biofrontera AG and Biosynth AG settle legal issues amicably

[29 Aug 2014] Biofrontera AG ("Biofrontera" or "the Company") Half Year Results Progress in business operations

[21 Aug 2014] Biofrontera AG: Pre-NDA meeting scheduled with FDA for the approval of Ameluz® and BF-RhodoLED®

[20 Aug 2014] Ad hoc: Biofrontera AG files litigation against former supplier

[18 Aug 2014] Biofrontera AG: Belixos® now available through Amazon in Germany and UK

[06 Aug 2014] Biofrontera AG: First Ameluz® sales in Central Eastern European region

[02 Jul 2014] Biofrontera AG: PDT with Ameluz® is the most efficacious treatment option for actinic keratosis


Still looking?

Type in your search term below and click Enter

World News from SPi

Sector Publishing Intelligence [SPi'] publishes financial news from around the world FAST. For breaking news announcements from companies, blogs and commentators, SPi provides up to the minute, integrated news on all aspects of financial markets and financial services.

The SPi Financial News Search gets results from our extensive news archives containing 10’s of thousands of news reports. Intelligent cross referencing of stories and background gives readers and researchers highly relevant related information about topics and businesses in the finance sector.

Trending financial topics highlight the most recent themes in the news. Thousands of financial topics can be followed using RSS, or join hundreds of SPis Financial News followers on Twitter for instant news as soon as it’s published on SPi. @SPiFinancialSvc

SPi's extensive database of corporate information shows company details alongside breaking corporate news from the world’s largest news providers.

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us